Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects
Sponsor: Nventa Biopharmaceuticals Corporation
This PHASE1 trial investigates Cervical Intraepithelial Neoplasia and is currently ongoing. Nventa Biopharmaceuticals Corporation leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nventa Biopharmaceuticals Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Augusta, United States
- • Houston, United States
- • Los Angeles, United States
- • New York, United States
- • Oklahoma City, United States
- • Pleasant Grove, United States
- • San Diego, United States
- • South Salt Lake, United States